ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
|Articles|September 11, 2009
- ONCOLOGY Vol 23 No 10
- Volume 23
- Issue 10
New Drug Application Filed for Pixantrone
Cell Therapeutics, Inc, announced that the US Food and Drug Administration (FDA) has accepted and has filed for review the company’s New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). As we went to press, a Prescription Drug User Fee Act (PDUFA) date was to be established by the FDA regarding the review of the pixantrone NDA by September 4, 2009.
Advertisement
Cell Therapeutics, Inc, announced that the US Food and Drug Administration (FDA) has accepted and has filed for review the company’s New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). As we went to press, a Prescription Drug User Fee Act (PDUFA) date was to be established by the FDA regarding the review of the pixantrone NDA by September 4, 2009.
Articles in this issue
about 17 years ago
Radical Prostatectomy Reigns Supremeabout 17 years ago
Gingerabout 17 years ago
More Questions About Neoadjuvant Chemotherapy in Lung Cancerabout 17 years ago
Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancerabout 17 years ago
Preoperative Therapy for Early-Stage NSCLC: Opportunities and Challengesabout 17 years ago
FDA Approves First Maintenance Drug Therapy for Advanced Lung Cancerabout 17 years ago
Accelerated Approval Granted for Bevacizumab in Glioblastomaabout 17 years ago
New Opioid Pain Reliever Approved With Required Risk-Reduction Planabout 17 years ago
FDA Extends Review of OfatumumabAdvertisement
Related to this article
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
3
WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5